



## **JIWA BIO-PHARM HOLDINGS LIMITED**

**積華生物醫藥控股有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 2327)**

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board wishes to announce that Mr. Seet Lip Chai (“Dr. Seet”) has been appointed as an Independent Non-executive Director with effect from 1 September 2005.

Dr. Seet, aged 62, holds degrees of Bachelor of Medicine and Bachelor of Surgery, a Diploma in Public Health (with Distinction) from the University of Singapore and is a Fellow of the Academy of Medicine, Singapore.

Dr. Seet has held senior management positions in major global pharmaceutical companies such as Ciba-Geigy, SmithKline Beecham and GlaxoWellcome both in the Asian Region and in China prior to taking up an academic position as Associate Professor in Strategy and Entrepreneurship in Nanyang Technological University, Singapore in 1999. Besides holding Directorships in several private companies, Dr Seet is presently also an Independent Non-executive Director and Non-Executive Chairman of the Board of Directors of Rockeby biomed Ltd, a medical diagnostic company listed on the Australian Stock Exchange (RBY.ASX). Save as disclosed above, Dr. Seet has not held any directorship in any listed public companies in the last three years.

Dr. Seet has no relationship with any directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Dr. Seet does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

The Company and Dr. Seet have entered into a service contract on 15 August 2005 which provides that Dr. Seet’s proposed length of service with the Company will be 1 year with effect from 1 September 2005 subject to re-election in the next general meeting. The remuneration of Dr. Seet is HK\$100,000 per annum, which has been determined on the basis of prevailing market conditions and his role and responsibilities.

The Board welcomes Dr. Seet and believes that his joining with the Board will be beneficial to the Company. Saved as disclosed herein, the Board is not aware of any other matters relating to the appointment of Dr. Seet as an Independent Non-executive Director that needs to be brought to the attention of the shareholders of the Company.

The Board also wishes to announce that Mr. Soo Ping Shu, Samuel, an Independent Non-executive Director of the Company, shall cease to hold office upon expiry (31 August 2005) of his service contract.

The Board would like to take this opportunity to express its gratitude to Mr. Soo for his contribution to the Company during his term of services.

As at the date of this announcement, the board of directors of the Company comprises Mr. Lau Yau Bor, Mr. Lau Kin Tung and Madam Chan Hing Ming as Executive Directors and Mr. Fung Tze Wa, Mr. Choy Ping Sheung and Mr. Soo Ping Shu, Samuel as Independent Non-executive Directors.

By Order of the Board  
**Jiwa Bio-Pharm Holdings Limited**  
**Lau Kin Tung**  
*Vice Chairman and Chief Executive Officer*

15 August 2005, Hong Kong

\* *for identification only*

“Please also refer to the published version of this announcement in China Daily”